| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,413,000 |
| Market
Cap: |
9.16(B) |
| Last
Volume: |
875,140 |
Avg
Vol: |
504,506 |
| 52
Week Range: |
$114.17 - $208.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
40,296 |
45,669 |
50,307 |
151,828 |
| Total Sell Value |
$7,357,263 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
| Total People Sold |
2 |
4 |
5 |
6 |
| Total Sell Transactions |
3 |
5 |
7 |
17 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bylund James |
Chief Operating Officer |
• – – |
2024-03-04 |
4 |
D |
$193.99 |
$38,216 |
D/D |
(197) |
22,263 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2024-03-04 |
4 |
D |
$193.99 |
$25,413 |
D/D |
(131) |
28,139 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• – – |
2024-03-04 |
4 |
D |
$193.99 |
$215,523 |
D/D |
(1,111) |
212,097 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2024-03-04 |
4 |
D |
$192.71 |
$88,839 |
D/D |
(461) |
28,270 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50 |
22,460 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• – – |
2024-03-01 |
4 |
D |
$191.79 |
$637,126 |
D/D |
(3,322) |
213,208 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-03-01 |
4 |
D |
$191.79 |
$157,268 |
D/D |
(820) |
22,410 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2024-03-01 |
4 |
D |
$191.79 |
$86,881 |
D/D |
(453) |
27,027 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2024-03-01 |
4 |
D |
$191.79 |
$85,730 |
D/D |
(447) |
28,731 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• – – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,504 |
216,530 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
404 |
23,230 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
404 |
27,480 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
391 |
29,178 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
19,719 |
214,026 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,520 |
27,076 |
|
- |
|
| Loeillot Olivier |
President and CCO |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,880 |
15,786 |
|
- |
|
| Garland Jason K |
CFO |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,540 |
8,043 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,691 |
22,826 |
|
- |
|
| Dawes Karen A |
|
– • – |
2024-02-27 |
4 |
S |
$193.35 |
$193,350 |
D/D |
(1,000) |
87,367 |
|
23% |
|
| Dawes Karen A |
|
– • – |
2024-02-27 |
4 |
OE |
$42.07 |
$194,616 |
D/D |
4,626 |
88,367 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-02-23 |
4 |
S |
$198.08 |
$866,204 |
D/D |
(4,373) |
14,135 |
|
24% |
|
| Bylund James |
Chief Operating Officer |
• – – |
2024-02-23 |
4 |
OE |
$94.33 |
$88,670 |
D/D |
940 |
18,508 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• – – |
2023-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
194,307 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2023-11-10 |
4 |
S |
$147.13 |
$557,328 |
D/D |
(3,788) |
28,787 |
|
-34% |
|
| Loeillot Olivier |
President and CCO |
• – – |
2023-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,906 |
12,906 |
|
- |
|
647 Records found
|
|
Page 2 of 26 |
|
|
0.91 (0.61%) 
